Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.32 - $7.33 $342,076 - $471,319
64,300 Added 107.17%
124,300 $911,000
Q2 2024

Aug 14, 2024

BUY
$4.81 - $5.78 $288,600 - $346,800
60,000 New
60,000 $342,000
Q4 2023

Feb 14, 2024

BUY
$7.13 - $9.49 $1.2 Million - $1.59 Million
168,000 Added 336.0%
218,000 $1.96 Million
Q2 2023

Aug 14, 2023

SELL
$8.96 - $11.69 $896,000 - $1.17 Million
-100,000 Reduced 66.67%
50,000 $484,000
Q1 2023

May 15, 2023

BUY
$5.94 - $11.27 $623,700 - $1.18 Million
105,000 Added 233.33%
150,000 $1.64 Million
Q4 2022

Feb 14, 2023

SELL
$4.11 - $8.14 $102,750 - $203,500
-25,000 Reduced 35.71%
45,000 $194,000
Q3 2022

Nov 14, 2022

BUY
$6.66 - $12.39 $66,600 - $123,900
10,000 Added 16.67%
70,000 $525,000
Q1 2022

May 13, 2022

SELL
$10.05 - $22.48 $1.38 Million - $3.08 Million
-137,100 Reduced 69.56%
60,000 $743,000
Q4 2021

Feb 11, 2022

BUY
$17.78 - $33.08 $1.9 Million - $3.54 Million
107,100 Added 119.0%
197,100 $4.51 Million
Q3 2021

Nov 12, 2021

SELL
$10.93 - $23.55 $765,100 - $1.65 Million
-70,000 Reduced 43.75%
90,000 $1.99 Million
Q2 2021

Aug 16, 2021

BUY
$10.0 - $14.52 $400,000 - $580,800
40,000 Added 33.33%
160,000 $2.07 Million
Q1 2021

May 17, 2021

SELL
$12.3 - $18.73 $1.24 Million - $1.9 Million
-101,200 Reduced 45.75%
120,000 $1.56 Million
Q4 2020

Feb 16, 2021

BUY
$12.94 - $16.05 $144,928 - $179,760
11,200 Added 5.33%
221,200 $3.06 Million
Q3 2020

Nov 16, 2020

SELL
$13.19 - $16.66 $820,418 - $1.04 Million
-62,200 Reduced 22.85%
210,000 $3.09 Million
Q2 2020

Aug 14, 2020

SELL
$14.12 - $18.33 $847,200 - $1.1 Million
-60,000 Reduced 18.06%
272,200 $4.42 Million
Q1 2020

May 15, 2020

BUY
$11.34 - $21.46 $3.77 Million - $7.13 Million
332,200 New
332,200 $4.82 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.28B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.